Advertisement

Whole-Exome Sequencing (WES) for Illumina Short Read Sequencers Using Solution-Based Capture

Protocol
First Online:
Part of the Methods in Molecular Biology book series (MIMB, volume 2076)

Abstract

Next-generation sequencing (NGS) is transforming clinical research and diagnostics, vastly enhancing our ability to identify novel disease-causing genetic mutations and perform comprehensive diagnostic testing in the clinic. Whole-exome sequencing (WES) is a commonly used method which captures the majority of coding regions of the genome for sequencing, as these regions contain the majority of disease-causing mutations. The clinical applications of WES are not limited to diagnosis; the technique can be employed to help determine an optimal therapeutic strategy for a patient considering their mutation profile. WES may also be used to predict a patient’s risk of developing a disease, e.g., type 2 diabetes (T2D), and can therefore be used to tailor advice for the patient about lifestyle choices that could mitigate those risks. Thus, genome sequencing strategies, such as WES, underpin the emerging field of personalized medicine. Initiatives also exist for sharing WES data in public repositories, e.g., the Exome Aggregation Consortium (ExAC) database. In time, by mining these valuable data resources, we will acquire a better understanding of the roles of both single rare mutations and specific combinations of common mutations (mutation signatures) in the pathology of complex diseases such as diabetes.

Herein, we describe a protocol for performing WES on genomic DNA extracted from blood or saliva. Starting with gDNA extraction, we document preparation of a library for sequencing on Illumina instruments and the enrichment of the protein-coding regions from the library using the Roche NimbleGen SeqCap EZ Exome v3 kit; a solution-based capture method. We include details of how to efficiently purify the products of each step using the AMPure XP System and describe how to use qPCR to test the efficiency of capture, and thus determine finished library quality.

Key words

NGS WES Exome-seq Sequencing AMPure XP NEBNext Illumina qPCR 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Prasad RB, Groop L (2015) Genetics of type 2 diabetes—pitfalls and possibilities. Genes 6(1):87–123CrossRefPubMedGoogle Scholar
  2. 2.
    Murea M, Ma L, Freedman BI (2012) Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications. Rev Diabet Stud 9(1):6–22CrossRefPubMedGoogle Scholar
  3. 3.
    Lander ES, Linton LM, Birren B et al (2001) Initial sequencing and analysis of the human genome. Nature 409(6822):860–921CrossRefGoogle Scholar
  4. 4.
    Muir P, Li S, Lou S et al (2016) The real cost of sequencing: scaling computation to keep pace with data generation. Genome Biol 17:53CrossRefPubMedGoogle Scholar
  5. 5.
    Wetterstrand KA (2016) DNA sequencing costs: data from the NHGRI genome sequencing program (GSP). www.genome.gov/sequencingcostsdata. Accessed 27 Feb 2017Google Scholar
  6. 6.
    Dorajoo R, Liu J, Boehm BO (2015) Genetics of type 2 diabetes and clinical utility. Genes 6:372–384CrossRefPubMedGoogle Scholar
  7. 7.
    Dickson SP, Wang K, Krantz I, Hakonarson H et al (2010) Rare variants create synthetic genome-wide associations. PLoS Biol 8:e1000294.  https://doi.org/10.1371/journal.pbio.1000294CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    Fuchsberger C, Flannick J, Teslovich TM et al (2016) The genetic architecture of type 2 diabetes. Nature 536(7614):41–47CrossRefPubMedGoogle Scholar
  9. 9.
    Katsanis SH, Katsanis N (2013) Molecular genetic testing and the future of clinical genomics. Nat Rev Genet 14(6):415–426CrossRefPubMedGoogle Scholar
  10. 10.
    Ellard S, Lango Allen H, De Franco E et al (2013) Improved genetic testing for monogenic diabetes using targeted next-generation sequencing. Diabetologia 56:1958CrossRefPubMedGoogle Scholar
  11. 11.
    Warr A, Robert C, Hume D et al (2015) Exome sequencing: current and future perspectives. G3 5(8):1543–1550CrossRefGoogle Scholar
  12. 12.
    Samorodnitsky E, Jewell BM, Hagopian R et al (2015) Evaluation of hybridization capture versus amplicon‐based methods for whole‐exome sequencing. Hum Mutat 36(9):903–914CrossRefPubMedGoogle Scholar
  13. 13.
    Lelieveld SH, Spielmann M, Mundlos S et al (2015) Comparison of exome and genome sequencing technologies for the complete capture of protein‐coding regions. Hum Mutat 36(8):815–822CrossRefPubMedGoogle Scholar
  14. 14.
    Bonnefond A, Durand E, Sand O et al (2010) Molecular diagnosis of neonatal diabetes mellitus using next-generation sequencing of the whole exome. PLoS One 5(10):e13630CrossRefPubMedGoogle Scholar
  15. 15.
    Shaer N, Khan JJ, Dallol A, Abuzenadah A (2014) Diabetes personalized: the use of whole-exome sequencing in order to identify familial type 2 diabetes mellitus susceptibility factors. BMC Genomics 15(Suppl 2):P51CrossRefPubMedGoogle Scholar
  16. 16.
    Ellingford JM, Barton S, Bhaskar S et al (2016) Whole genome sequencing increases molecular diagnostic yield compared with current diagnostic testing for inherited retinal disease. Ophthalmology 123(5):1143–1150CrossRefPubMedGoogle Scholar
  17. 17.
    Meienberg J, Zerjavic K, Keller I et al (2015) New insights into the performance of human whole-exome capture platforms. Nucleic Acids Res 43(11):e76CrossRefPubMedGoogle Scholar
  18. 18.
    Rabbani B, Tekin M, Mahdieh N (2014) The promise of whole-exome sequencing in medical genetics. J Hum Genet 59(1):5–15CrossRefGoogle Scholar
  19. 19.
    Kwak SH, Jung CH, Ahn CH et al (2016) Clinical whole exome sequencing in early onset diabetes patients. Diabetes Res Clin Pract 122:71–77CrossRefGoogle Scholar
  20. 20.
    Lyssenko V, Laakso M (2013) Genetic screening for the risk of type 2 diabetes: worthless or valuable? Diabetes Care 36(Suppl 2):S120–S126CrossRefPubMedGoogle Scholar
  21. 21.
    Exome Aggregation Consortium, Lek M, Karczewski KJ, Minikel EV et al (2016) Analysis of protein-coding genetic variation in 60,706 humans. Nature 536(7616):285–291CrossRefPubMedGoogle Scholar
  22. 22.
    Goodwin S, McPherson JD, McCombie WR (2016) Coming of age: ten years of next-generation sequencing technologies. Nat Rev Genet 17(6):333–351CrossRefGoogle Scholar
  23. 23.
    Levy SE, Myers RM (2016) Advancements in next-generation sequencing. Annu Rev Genomics Hum Genet 17:95–115CrossRefGoogle Scholar
  24. 24.
    DeAngelis MM, Wang DG, Hawkins TL (1995) Solid-phase reversible immobilization for the isolation of PCR products. Nucleic Acids Res 23(22):4742–4743CrossRefPubMedGoogle Scholar
  25. 25.
    Chilamakuri CSR, Lorenz S, Madoui M-A, Vodák D, Sun J, Hovig E, Myklebost O, Meza-Zepeda LA (2014) Performance comparison of four exome capture systems for deep sequencing. BMC Genomics 15(1):449CrossRefPubMedGoogle Scholar
  26. 26.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  1. 1.Sema4, a Mount Sinai ventureStamfordUSA

Personalised recommendations

Cite protocol

Buy options